Indiana University
MAPS & DIRECTIONS Maps FIND PEOPLE Find People
Research

Research on:  ALS
Project Title:  A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study  to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with  Amyotrophic Lateral Sclerosis
Faculty:  Pascuzzi, Robert Mark
Sponsor:  CYTOKINETICS


Research on:  ALS
Project Title:  A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study  to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients with  Amyotrophic Lateral Sclerosis
Faculty:  Pascuzzi, Robert Mark
Sponsor:  CYTOKINETICS


Research on:  ALS
Project Title:  An Open Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects with Amyotrophic Lateral Sclerosis (223AS304)
Faculty:  Pascuzzi, Robert Mark
Sponsor:  BIOGEN IDEC INC


Research on:
  Alzheimer’s Disease
Project Title:  Dominantly Inherited Alzheimer Network
Faculty:  Ghetti, Bernardino
Sponsor:  WASHINGTON UNIV


Research on:  Alzheimer’s Disease
Project Title:  A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer’s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following repeated i.m. injections of adjuvanted C
Faculty:  Farlow, Martin Rhys
Sponsor:  NOVARTIS PHARM CORP


Research on:  Alzheimer’s Disease
Project Title:  A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimers Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody response following repeated i.m. injections of adjuvanted C
Faculty:  Farlow, Martin Rhys
Sponsor:  NOVARTIS PHARM CORP


Research on:  Alzheimer’s Disease
Project Title:  Alzheimer Disease Neuroimaging Initiative: Cognitive Normal, Late Mild Cognitive Impaired and Early Cognitive Impaired Subjects from ADNI-1 and ADNI-GO (ADNI-2)
Faculty:  Farlow, Martin Rhys
Sponsor:  UNIV CALIF SAN DIEGO


Research on:  Alzheimer’s Disease
Project Title:  Alzheimer Disease Neuroimaging Initiative: Cognitive Normal, Late Mild Cognitive Impaired and Early Cognitive Impaired Subjects from ADNI-1 and ADNI-GO (ADNI-2)
Faculty:  Farlow, Martin Rhys
Sponsor:  UNIV CALIF SAN DIEGO


Research on:  Alzheimer’s Disease
Project Title:  Alzheimer Disease Neuroimaging Initiative: Cognitive Normal, Late Mild Cognitive Impaired and Early Cognitive Impaired Subjects from ADNI-1 and ADNI-GO (ADNI-2)
Faculty:  Farlow, Martin Rhys
Sponsor:  UNIV CALIF SAN DIEGO


Research on:  Alzheimer’s Disease
Project Title:  A Multicenter, Open-label, Long-term Safety Extension of phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer’s Disease
Faculty:  Farlow, Martin Rhys
Sponsor:  GENENTECH INC


Research on:  Alzheimer’s Disease
Project Title:  Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid I? Antibody in Patients with Alzheimer’s Disease
Faculty:  Farlow, Martin Rhys
Sponsor:  LILLY USA, LLC


Research on:  Alzheimer’s Disease
Project Title:  Continued Efficacy and Safety Monitoring ofSolanezumab, an Anti-Amyloid Beta Antibody in Patientswith Alzheimer’s Disease
Faculty:  Farlow, Martin Rhys
Sponsor:  ELI LILLY & CO


Research on:  Alzheimer’s Disease
Project Title:  Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid Beta Antibody in Patients with Alzheimer's Disease (H8A-MC-LZAO)
Faculty:  Farlow, Martin Rhys
Sponsor:  ELI LILLY & CO


Research on:  Alzheimer’s Disease
Project Title:  A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects with Prodromal or Mild Alzheimer's Disease  BART 221AD103
Faculty:  Farlow, Martin Rhys
Sponsor:  BIOGEN IDEC INC


Research on:  Alzheimer’s Disease
Project Title:  A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects with Prodromal or Mild Alzheimer’s Disease (221AD103)
Faculty:  Farlow, Martin Rhys
Sponsor:  BIOGEN IDEC INC


Research on:  Alzheimer’s Disease
Project Title:  A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects with Prodromal or Mild Alzheimer's Disease  BART 221AD103
Faculty:  Farlow, Martin Rhys
Sponsor:  BIOGEN IDEC INC


Research on:  Alzheimer’s Disease
Project Title:  A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]AZD4694 PET in the Detection of Beta Amyloid in Subjects with Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
Faculty:  Farlow, Martin Rhys
Sponsor:  NAVIDEA BIOPHARM


Research on:  Alzheimer’s Disease
Project Title:  A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimers Disease
Faculty:  Farlow, Martin Rhys
Sponsor:  EISAI MEDICAL RESEARCH INC.


Research on:  Alzheimer’s Disease
Project Title:  A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease
Faculty:  Farlow, Martin Rhys
Sponsor:  EISAI MEDICAL RESEARCH INC.


Research on:  Alzheimer’s Disease
Project Title:  A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease
Faculty:  Farlow, Martin Rhys
Sponsor:  EISAI MEDICAL RESEARCH INC.



Research on:
  Alzheimer’s Disease
Project Title:  Data Analysis and Publications (DAPC)
Faculty:  Farlow, Martin Rhys
Sponsor:  UNIV CALIF SAN DIEGO


Research on:  Alzheimer’s Disease
Project Title:  Data Analysis and Publication Committee (DAPC) Semagacestat Committee (DAPC)
Faculty:  Farlow, Martin Rhys
Sponsor:  UNIV CALIF SAN DIEGO


Research on:  Alzheimer’s Disease
Project Title:  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer's Diseases, Protocol # ABE4869G
Faculty:  Farlow, Martin Rhys
Sponsor:  GENENTECH INC


Research on:  Alzheimer’s Disease
Project Title:  A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics  of Intravenous Infusions of BAN2401 in Su
Faculty:  Farlow, Martin Rhys
Sponsor:  EISAI MEDICAL RESEARCH INC.


Research on:  Alzheimer’s Disease
Project Title:  A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics  of Intravenous Infusions of BAN2401 in Su
Faculty:  Farlow, Martin Rhys
Sponsor:  EISAI MEDICAL RESEARCH INC.


Research on:  Alzheimer’s Disease
Project Title:  A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26-Week Open-label Extension
Faculty:  Farlow, Martin Rhys
Sponsor:  ACCERA


Research on:  Alzheimer’s Disease
Project Title:  Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People Over 75 Years Old (ADC-030 HBA)
Faculty:  Farlow, Martin Rhys
Sponsor:  UNIV CALIF SAN DIEGO


Research on:  Alzheimer’s Disease
Project Title:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer
Faculty:  Hake, Ann Marie
Sponsor:  JANSSEN ALZHEIMER IM


Research on:  Alzheimer’s Disease
Project Title:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer
Faculty:  Matthews, Brandy Rene
Sponsor:  JANSSEN ALZHEIMER IM


Research on:  Alzheimer’s Disease
Project Title:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer's Di
Faculty:  Matthews, Brandy Rene
Sponsor:  JANSSEN ALZHEIMER IM


Research on:  Epilepsy
Project Title:  Epilepsy Clinic and Services
Faculty:  Markand, Omkar N
Sponsor:  IFSSA


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC



Research on:  Epilepsy

Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Stimulation of the Anterior Nucleus of the Thalamus of Epilepsy (SANTE)
Faculty:  Salanova, Vicenta
Sponsor:  MEDTRONIC INC


Research on:  Epilepsy
Project Title:  Responsive Neurostimulator (RNS) System Long-term Treatment Clinical Investigation
Faculty:  Salanova, Vicenta
Sponsor:  NEUROPACE, INC.


Research on:  Epilepsy
Project Title:  Responsive Neurostimulator (RNS) System Long-term Treatment Clinical Investigation
Faculty:  Salanova, Vicenta
Sponsor:  NEUROPACE, INC.



Research on:  Epilepsy

Project Title:  Radiosurgery vs lobectomy for temporal lobe epilepsy: Phase 3 Clinical Trial
Faculty:  Salanova, Vicenta
Sponsor:  UNIV CALIF SF


Research on:  Epilepsy
Project Title:  A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Pregabalin as Adjunctive Therapy in Pediatric and Adult Subjects with Primary Generalized Tonic-Clonic Seizures (208238 A0081105)
Faculty:  Salanova, Vicenta
Sponsor:  PFIZER, INC


Research on:  Movement Disorders
Project Title:  Continuation of NET-PD Trials at Indiana University
Faculty:  Wojcieszek, Joanne M.
Sponsor:  NIH-NINDS


Research on:  Movement Disorders
Project Title:  A multi-center, North American, open-label extension study of pridopidine (ACR16) in the symptomatic treatment of Huntington Disease (OPEN-HART)
Faculty:  Wojcieszek, Joanne M.
Sponsor:  UNIV OF ROCHESTER


Research on:  Movement Disorders
Project Title:  A multi-center, North American, open-label extension study of pridopidine (ACR16) in the symptomatic treatment of Huntington Disease (OPEN-HART)
Faculty:  Wojcieszek, Joanne M.
Sponsor:  UNIV OF ROCHESTER


Research on:  Movement Disorders
Project Title:  An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias
Faculty:  Wojcieszek, Joanne M.
Sponsor:  NOVARTIS PHARM CORP


Research on:  Movement Disorders
Project Title:  PROGENI Family Study
Faculty:  Foroud, Tatiana M
Sponsor:  MICHAEL J FOX FDN



Research on:
  Movement Disorders
Project Title:  Impact of Medical and Surgical Therapies on Communication in PD
Faculty:  Zauber, S Elizabeth
Sponsor:  IU HEALTH


Research on:  Movement Disorders
Project Title:  Creatine Safety, Tolerability, and Efficacy in Huntington's Disease:  CREST-E
Faculty:  Zauber, S. Elizabeth
Sponsor:  MASS GENERAL HOSPITAL


Research on:  Multiple Sclerosis
Project Title:  A 6-Month, Randomized, Active Comparator, Open-label, Multicenter Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy c
Faculty:  Mattson, David H.
Sponsor:  NOVARTIS PHARM CORP


Research on:  Multiple Sclerosis
Project Title:  A 6-Month, Randomized, Active Comparator, Open-label, Multicenter Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy
Faculty:  Mattson, David H.
Sponsor:  NOVARTIS PHARM CORP


Research on:  Multiple Sclerosis
Project Title:  A 26 Week Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (ONO-4641POU007)
Faculty:  Mattson, David H.
Sponsor:  ONO PHARMS USA


Research on:  Multiple Sclerosis
Project Title:  A 26 Week Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (ONO-4641POU007)
Faculty:  Mattson, David H.
Sponsor:  ONO PHARMS USA


Research on:  Multiple Sclerosis
Project Title:  A Safety and Efficacy Extension Study of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (ONO-4641POU007)
Faculty:  Mattson, David H.
Sponsor:  ONO PHARMS USA



Research on:
  Multiple Sclerosis
Project Title:  Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex? (Interferon Beta-1a) in Patients with Relapsing-Remitting Multiple
Faculty:  Mattson, David H.
Sponsor:  BIOGEN IDEC INC


Research on:  Multiple Sclerosis
Project Title:  A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitt
Faculty:  Mattson, David H.
Sponsor:  NOVARTIS PHARM CORP


Research on:  Multiple Sclerosis
Project Title:  A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis (WA25046 RO 496-4913)
Faculty:  Mattson, David H.
Sponsor:  HOFFMANN LA ROCHE


Research on:  Multiple Sclerosis
Project Title:  A Phase 1/2 Randomized, Dose-finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis
Faculty:  Mattson, David H.
Sponsor:  MEDIMMUNE INC


Research on:  Multiple Sclerosis
Project Title:  A Phase 1/2 Randomized, Dose-finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis
Faculty:  Mattson, David H.
Sponsor:  MEDIMMUNE INC


Research on:  Multiple Sclerosis
Project Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (101MS326)
Faculty:  Mattson, David H.
Sponsor:  BIOGEN IDEC INC



Research on:
  Multiple Sclerosis
Project Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (101MS326)
Faculty:  Mattson, David H.
Sponsor:  BIOGEN IDEC INC


Research on:  Multiple Sclerosis
Project Title:  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis (101MS326)
Faculty:  Mattson, David H.
Sponsor:  BIOGEN IDEC INC


Research on:  Multiple Sclerosis
Project Title:  A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of rHIgM22 in Patients with Multiple Sclerosis (IM22-MS-1004)
Faculty:  Mattson, David H.
Sponsor:  ACORDA THERAPEUTICS, INC.


Research on:  Multiple Sclerosis
Project Title:  AC-058B202 - Multicenter, randomized, double-blind, parallel-group extension study AC-058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ACT-128800, and oral S1P1 receptor agonist, in patients with relaps
Faculty:  Mattson, David H.
Sponsor:  ACTELION CLINICAL RES


Research on:  Multiple Sclerosis
Project Title:  Multicenter, randomized, double-blind, parallel-group extension to studyAC-058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20,and 40 mg/day ponesimod, an oral S1P1 receptor agonist, in patients withrelapsing-remittin
Faculty:  Mattson, David H.
Sponsor:  ACTELION CLINICAL RES


Research on:  Multiple Sclerosis
Project Title:  An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Faculty:  Mattson, David H.
Sponsor:  GENZYME CORPORATION



Research on:
  Multiple Sclerosis
Project Title:  An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
Faculty:  Mattson, David H.
Sponsor:  GENZYME CORPORATION


Research on:  Multiple Sclerosis
Project Title:  A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects with Relapsing Multiple Scl
Faculty:  Mattson, David H.
Sponsor:  TEVA NEUROSCIENCE INC


Research on:  Multiple Sclerosis
Project Title:  A PHASE I, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING SINGLE-DOSE STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF INTRAVENOUS VX15/2503 IN PATIENTS WITH MULTIPLE SCLEROSIS
Faculty:  Mattson, David H.
Sponsor:  VACCINEX


Research on:  Neuropathy
Project Title:  A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 in Patient with Painful Diabetic Neuropathy
Faculty:  Kincaid, John C
Sponsor:  MERCK SHARP & DOHME RESEARCH


Research on:  Neuropathy
Project Title:  A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 in Patient with Painful Diabetic Neuropathy
Faculty:  Kincaid, John C
Sponsor:  MERCK SHARP & DOHME RESEARCH


Research on:  Neuropathy
Project Title:  A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 in Patient with Painful Diabetic Neuropathy
Faculty:  Kincaid, John C
Sponsor:  MERCK SHARP & DOHME RESEARCH


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neuropsychology
Project Title:  Dopaminergic Function in Alcoholism
Faculty:  Kareken, David A.
Sponsor:  NIH-NIAAA


Research on:  Neurofibromatosis
Project Title:  Biomarkers of cardiovascular disease as predictors of NF1 severity
Faculty:  Ingram, David A
Sponsor:  TUMOR FOUNDATION


Research on:  Neuromuscular Disease
Project Title:  Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects with Known Lambert-Eaton Myasthenic Syndrome,
Faculty:  Pascuzzi, Robert Mark
Sponsor:  JACOBUS PHARM CO



Research on:
  Neuromuscular Disease
Project Title:  Phase II Trial of Methotrexate in Myasthenia Gravis
Faculty:  Pascuzzi, Robert Mark
Sponsor:  UNIV KANSAS MED CTR


Research on:  Stroke
Project Title:  Outcomes and Processes of Care in Intracerebral Hemorrhage
Faculty:  Mackey, Jason Scott
Sponsor:  IU HEALTH


Research on:  Stroke
Project Title:  Insulin Resistance Intervention after Stroke
Faculty:  Fleck, James Dennis
Sponsor:  YALE SCH OF MEDICINE


Research on:  Stroke
Project Title:  Insulin Resistance Intervention and Stroke
Faculty:  Fleck, James Dennis
Sponsor:  YALE SCH OF MEDICINE